Get the Stockscreener App
0.2932
2.95%
-0.0089
After Hours:
.30
0.0068
+2.32%
Cellectar Biosciences Inc stock is traded at $0.2932, with a volume of 603.32K.
It is down -2.95% in the last 24 hours and up +6.15% over the past month.
See More
Previous Close:
$0.3021
Open:
$0.3
24h Volume:
603.32K
Relative Volume:
0.37
Market Cap:
$13.51M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.0902
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-18.60%
1M Performance:
+6.15%
6M Performance:
-86.43%
1Y Performance:
-92.63%
1-Day Range:
$0.2909
$0.3128
1-Week Range:
$0.2899
$0.369
52-Week Range:
$0.224
$4.1499
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2932 | 13.51M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Enhances CEO and COO Severance Benefits - TipRanks
What is Roth Capital’s Estimate for CLRB FY2029 Earnings? - Defense World
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlight - GuruFocus.com
Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings - TipRanks
Cellectar Biosciences Advances Cancer Drug Pipeline - TipRanks
Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges - TipRanks
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - StockTitan
Cellectar Biosciences Provides Update on FDA Regulatory Path for Iopofosine I 131 in Waldenström Macroglobulinemia and Advances Phase 1 Trials for New Radioconjugates - Nasdaq
Cellectar Biosciences COO acquires $8,400 in stock By Investing.com - Investing.com Canada
Cellectar Biosciences COO acquires $8,400 in stock - Investing.com India
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Quantisnow
Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq
Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan
Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - stocksregister.com
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire
Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq
When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow
A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan
Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News
Cellectar faces Nasdaq delisting over share price rule - MSN
Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):